Kewaunee Scientific Co. (NASDAQ:KEQU - Get Free Report) CEO Thomas David Hull III sold 213 shares of the firm's stock in a transaction on Friday, March 21st. The stock was sold at an average price of $48.53, for a total value of $10,336.89. Following the completion of the transaction, the chief executive officer now directly owns 40,916 shares of the company's stock, valued at $1,985,653.48. The trade was a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Thomas David Hull III also recently made the following trade(s):
- On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $45.63, for a total value of $136,890.00.
- On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The shares were sold at an average price of $60.08, for a total value of $82,189.44.
- On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $63.01, for a total transaction of $126,020.00.
Kewaunee Scientific Trading Down 3.3 %
Shares of KEQU stock opened at $44.96 on Tuesday. The company has a market capitalization of $128.36 million, a PE ratio of 7.13 and a beta of 0.71. Kewaunee Scientific Co. has a 52-week low of $30.82 and a 52-week high of $71.33. The business's fifty day moving average is $57.26 and its 200 day moving average is $47.64. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.13 and a current ratio of 2.64.
Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last released its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 earnings per share for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The firm had revenue of $67.17 million for the quarter.
Institutional Investors Weigh In On Kewaunee Scientific
Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in shares of Kewaunee Scientific by 2,605.9% in the 4th quarter. Bank of America Corp DE now owns 460 shares of the technology company's stock worth $28,000 after buying an additional 443 shares during the last quarter. IFP Advisors Inc purchased a new position in Kewaunee Scientific in the fourth quarter worth $36,000. O Shaughnessy Asset Management LLC increased its stake in Kewaunee Scientific by 3.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 28,008 shares of the technology company's stock valued at $1,733,000 after acquiring an additional 891 shares during the last quarter. JPMorgan Chase & Co. raised its position in Kewaunee Scientific by 18,000.0% during the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company's stock valued at $30,000 after purchasing an additional 900 shares in the last quarter. Finally, Ritholtz Wealth Management lifted its stake in Kewaunee Scientific by 15.6% during the fourth quarter. Ritholtz Wealth Management now owns 12,619 shares of the technology company's stock worth $781,000 after purchasing an additional 1,706 shares during the last quarter. 32.69% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, StockNews.com lowered shares of Kewaunee Scientific from a "buy" rating to a "hold" rating in a report on Friday, March 14th.
View Our Latest Report on KEQU
About Kewaunee Scientific
(
Get Free Report)
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
